Helus Pharma (NASDAQ: HELP) (Cboe CA: HELP) has priced an underwritten public offering of 10.3 million common shares at $4.85 per share, aiming to raise gross proceeds of approximately $50 million. The offering, managed by joint bookrunning managers Cantor and Barclays, is expected to close on June 25, 2026, pending customary conditions and regulatory approvals. This capital infusion is a critical step for the clinical-stage pharmaceutical company as it seeks to advance its pipeline of novel serotonergic agonists (NSAs) designed to treat major depressive disorder (MDD), generalized anxiety disorder (GAD), and other mental health conditions.
The net proceeds will primarily fund the development of HLP003, a proprietary NSA currently in Phase 3 clinical trials for adjunctive treatment of MDD. Helus Pharma anticipates topline data from the Phase 3 APPROACH study in the fourth quarter of 2026. HLP003 has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration, underscoring its potential to offer durable improvements for patients who do not respond adequately to existing therapies. Additionally, funds will support HLP004, in Phase 2 for GAD, and the HLP005 program. Remaining proceeds will be allocated to working capital and general corporate purposes.
This offering comes at a pivotal time for Helus Pharma, which operates under the commercial name Cybin Inc. The company focuses on developing synthetic molecules that activate serotonin pathways to promote neuroplasticity, aiming to address the large unmet need in mental health. According to the World Health Organization, depression affects over 280 million people globally, and many patients fail to achieve remission with current treatments. Helus Pharma's NSAs are designed to provide faster onset and longer-lasting effects, potentially reshaping the treatment landscape.
The involvement of prominent underwriters like Cantor and Barclays signals confidence in Helus Pharma's clinical programs and market potential. The offering will dilute existing shareholders but provides necessary capital to reach key milestones. Investors should monitor the Phase 3 data readout in late 2026, which will be a major catalyst for the stock. For more details, the full press release is available at https://ibn.fm/yrchX.
Helus Pharma's progress could have significant implications for the mental health sector, where innovation is urgently needed. If HLP003 succeeds, it may offer a new option for the 30% of MDD patients who do not respond to standard antidepressants. The company's broader pipeline also targets GAD, a condition affecting millions, and other mental health disorders. The offering thus represents a bet on the potential of NSAs to transform care, but risks remain, including regulatory hurdles and competition from other psychedelic-inspired therapies.
